ARK Genomic Revolution ETF (ARKG)
- Previous Close
23.01 - Open
22.99 - Bid 23.14 x 900
- Ask 23.14 x 800
- Day's Range
22.66 - 23.33 - 52 Week Range
21.97 - 38.97 - Volume
926,743 - Avg. Volume
2,507,187 - Net Assets 1.61B
- NAV 23.00
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return -29.87%
- Beta (5Y Monthly) 1.70
- Expense Ratio (net) 0.75%
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
ARK ETF Trust
Fund Family
Health
Fund Category
1.61B
Net Assets
2014-10-31
Inception Date
Performance Overview: ARKG
Trailing returns as of 4/25/2024. Category is Health.
People Also Watch
Holdings: ARKG
Top 10 Holdings (47.86% of Total Assets)
Sector Weightings
Recent News: ARKG
Research Reports: ARKG
Analyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetAnalyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetAnalyst Report: Block, Inc.
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.
RatingPrice TargetAnalyst Report: Block Inc.
Block, which changed its name from Square in late 2021, is a technology platform company that provides payment and point-of-sale solutions to merchants worldwide. While changing its name, Block retained many of its well-known product titles, including its Square terminals. The company provides merchants with hardware for sales and payment solutions, along with software that converts iPads to payment terminals. Payments can be made on Square terminals via a tap, dip, or swipe, or through the company's Block Cash electronic tender. Block also provides CashApp, which allows consumers to send, spend, and store money on an app. Block processes transactions in the U.S. and internationally.
RatingPrice Target